The company appears on track to capitalise the asian market,...

The company appears on track to capitalise the asian market, huge upside expect 10c by end of week

SciGen taps into Vietnam market
13/01/04 By: Sarah Richards

SciGen Limited (SIE) announced today that it has secured registration of its second generation recombinant human insulin in Vietnam. The biotechnology company highlighted that this is the first registration of SciLin in the Asia Pacific Region.

SciGen said final preparations for the launch and sales of SciLin in Vietnam are underway and sales are expected to commence in coming weeks.


“Best estimates available indicate the size of the Vietnamese insulin market to be in excess of US$30 million,” boasted SciGen in a statement to the ASX.

SciGen advised that it has previously launched its third generation hepatitis B Vaccine in Vietnam and this has led the company to establish local networks, which will in turn facilitate sales both in the government and private markets.

“Registration applications for SciLin are still active in India, Indonesia and Pakistan with dossier preparation and other negotiations underway in other key territories in the Region such as China,” concluded the company.

At 1530 AEDT SciGen picked up 0.9c to 8.4c.